What diseases can bimetinib/bemetinib treat?

Binimetinib is a selective mitogen-activated protein kinase (MEK) inhibitor and a targeted therapy drug. This drug mainly blocks the RAS/RAF/MEK/ERK signaling pathway by inhibiting the activities of MEK1 and MEK2. This pathway is abnormally activated in a variety of tumor cells and is a key link in promoting the proliferation and survival of cancer cells. Bimetinib was originally developed to target malignant tumors with abnormal signals, especially solid tumors with BRAF gene mutations.

Currently, bimetinib is most commonly used to treat unresectable or metastatic melanoma harboring BRAF V600E or V600K mutations, often in combination with Encorafenib, another BRAF inhibitor. The combined treatment model of the two is clinically considered an important breakthrough for BRAF-mutant melanoma. Compared with single-agent therapy, it can significantly extend progression-free survival and reduce the risk of drug resistance. Overseas guidelines such as NCCN have included this combination regimen in first-line standard treatment recommendations for melanoma.

In addition, bimetinib is also used to treat adult patients with BRAF V600E mutation-positive metastatic non-small cell lung cancer. Some patients with these cancers have abnormal activation of the MAPK pathway, and MEK inhibitors target the key nodes of this pathway to intervene. Some early studies have shown that bimetinib, used alone or in combination with other targeted drugs, can improve the disease stability rate of some advanced patients and provide new treatment options for people who are ineffective with traditional treatments.

In the field of rare diseases, bimetinib is also used to study neurofibromatosis (NF1)-related tumors, cholangiocarcinoma and pancreatic cancer. Since the MEK pathway plays an important role in the signal regulation of various tumors, the research direction of bimetinib is constantly expanding. There are currently a number of international multi-center clinical trials underway to evaluate the effectiveness of the drug in combination with immune checkpoint inhibitors or chemotherapy drugs.

Reference materials:https://go.drugbank.com/drugs/DB11967